---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-089110"
form_type: "8-K"
ticker: "IMNM"
cik: "0001472012"
company_name: "Immunome Inc."
filed_at: "2023-08-09T23:59:59+00:00"
generated_at: "2026-06-11T21:48:24.392984+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Immunome Q2 net loss $5.6M; merger with Morphimmune and $125M PIPE deal announced

## Summary
- Q2 net loss $5.6M ($0.46 per share) on $4.3M AbbVie collaboration revenue; R&D $5.7M, G&A $4.2M.
- Cash and cash equivalents $38.4M as of June 30, 2023.
- Definitive merger agreement with Morphimmune to combine platforms, expected close by end of 2023.
- Clay Siegall, ex-Seagen CEO, to serve as Chairman and CEO of combined company.
- Concurrent $125M private placement from institutional investors to support 3 IND filings within 18 months post-close.

## SEC filing metadata
- accession: 0001104659-23-089110
- form_type: 8-K
- ticker: IMNM
- cik: 0001472012
- company_name: Immunome Inc.
- filed_at: 2023-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472012/000110465923089110/0001104659-23-089110-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472012/000110465923089110/tm2323035d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-089110
- JSON: https://secwatch.observer/filing/0001104659-23-089110.json
- Plain text: https://secwatch.observer/filing/0001104659-23-089110.txt

## Key facts
- Earnings Releases
  Immunome Inc. reported the second quarter ended June 30, 2023 results: net income $5.6 million, or $0.46 per share, EPS $0.46 per share.
  - Period: the second quarter ended June 30, 2023
  - Net income: $5.6 million, or $0.46 per share
  - EPS: $0.46 per share
  - Result: reported results
  source text: Net loss for the three months ended June 30, 2023 was $5.6 million, or $0.46 per share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1472012/000110465923089110/0001104659-23-089110-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.